Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meropenem-vaborbactam vs ceftazidime-avibactam for hospital-acquired/ventilator-associated bacterial pneumonia
CTR20255177Phase 3Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of meropenem + vaborbactam in hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), sponsored by Qilu Pharmaceutical. Started Jan 2026; status: active.
02
Drugs
meropenem + vaborbactam
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on CTR20255177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255177.